PROTAC BCR-ABL Degrader-2
PROTAC BCR-ABL Degrader-2 is a selective Bcr-AblT315 PROTAC degrader with a DC50 of 108.7 nM in Ba/F3 Bcr-AblT315I cells. PROTAC BCR-ABL Degrader-2 exhibits the most potent degradation efficacy with DR of 69.89% and 94.23% at 100 and 300 nM, respectively. PROTAC BCR-ABL Degrader-2 demonstrates high plasma exposure, and induces significant tumor regression and induces tumor cell apoptosis with a good safety profile in vivo. PROTAC BCR-ABL Degrader-2 can be used for chronic myeloid leukemia (CML) research.
(Pink: Bcr-Abl ligand (HY-15666); Blue: Cereblon ligand (HY-10984); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 2703834-25-5
- Formula: C48H46F3N9O6
- Molecular Weight:901.93
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
In Vitro
PROTAC BCR-ABL Degrader-2 (Compound 7o) (72 h) against K562, Ba/F3 Bcr-AbllT315I and Ba/F3 Bcr-AblWT with IC50s of 7.7, 26.8 and 4.2 nM[1].
PROTAC BCR-ABL Degrader-2 (0-300 nM) significantly decreases the level of Bcr-AblT315I protein with a DC50 = 108.7 nM in Ba/F3 Bcr-AblT315I cells[1].
PROTAC BCR-ABL Degrader-2 (0-300 nM, 0-48 h) induces Bcr-AblT315I protein level mediated by CRBN E3 ubiquitin pathway while appeared a “hook” effect in Bcr-AbllT315I cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ba/F3 Bcr-AblT315I and K562 cells
-
Concentration:100 nM
-
Incubation Time:0, 1, 2, 4, 6, 8, 10, 12, 24, 36 and 48 h
-
Result:Caused the degradation of Bcr-AblT315I protein in a time-dependent manner.
Reduced Bcr-AblT315I protein level substantially after 6h treatment while appeared a “hook” effect during 8-10h treatment.
Observed the maximum degradation after24h treatment.
Displayed a different trend for reducing Bcr-AblWT in K562cells with substantially reduction after 36h treatment (this different might be associated with the different states of E3 ligase in Ba/F3Bcr-AblT315I and K562 cells.).
-
Cell Line:MG132 (HY-13259) (20 ) Ba/F3 Bcr-AblT315I cells
-
Concentration:100 and 300 nM
-
Incubation Time:24 h
-
Result:Induced Bcr-AblT315I degradation rescuing by MG132.
In Vivo
PROTAC BCR-ABL Degrader-2 (10-20 mg/kg, i.p., once every two days for 14 days) displays significant anti-cancer activity and safety in the Ba/F3 Bcr-AblT315I mice xenograft models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ba/F3 cells expressing Bcr-AblT315I (2 x 106 cells/0.1 mL) induced-CB17-SCID mice [1]
-
Dosage:10 or 20 mg/kg
-
Administration:i.p., once every two days for 14 days
-
Result:Obviously sup pressed the growth of Ba/F3 Bcr-AblT315I xenograft tumor with a tumor growth inhibition (TGI) value of 90.8% at the dose of 20 mg/kg.
Induced the Bcr-AblT315I degradation and apoptosis.
Resulted no mortality or significant body weight loss.
Chemical Information
-
CAS No. 2703834-25-5
-
Molecular Weight 901.93
-
Formula C48H46F3N9O6
-
SMILES
O=C(C1=CC=C(C)C(C#CC2=CC3=C(NN=C3)N=C2)=C1)NC4=CC=C(CN5CCN(CCCCCCC(NC6=CC=CC(C(N7C8C(NC(CC8)=O)=O)=O)=C6C7=O)=O)CC5)C(C(F)(F)F)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
[1]. Jiang L, et al. Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta Pharm Sin B. 2021 May;11(5):1315-1328. [Content Brief]
[2]. Chen X, et al. Mighty mini-PROTACs: an emerging class of degraders. Eur J Med Chem. 2026 Jan 5;301:118202. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)